PC
PRTK

PA Capital’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

PA Capital’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-28,051
Closed -$113K – 184
2019
Q4 		$113K Buy
+28,051
New +$97.3K 0.1% 124

Other funds holding PRTK

OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
GAI
General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

PA Capital's PRTK Position: Q1 2020 in Review

PA Capital sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q1 2020, closing a stake of 28,051 shares — an estimated $113K sold.

PA Capital first reported a position in PRTK in Q4 2019 and held it in 1 quarter. The position peaked at $113K in Q4 2019. 85 funds tracked by Wall St. Rank hold PRTK as of Q1 2020.

  • PA Capital reported no remaining Paratek Pharmaceuticals, Inc. position as of Q1 2020 after selling out during the quarter.
  • PA Capital sold 28,051 Paratek Pharmaceuticals, Inc. shares in Q1 2020, an estimated $113K.
  • PA Capital first reported a position in Paratek Pharmaceuticals, Inc. in Q4 2019 and held it in 1 quarter.
  • PA Capital's Paratek Pharmaceuticals, Inc. position peaked at $113K in Q4 2019.
  • 85 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q1 2020.

Based on PA Capital's 13F filing for Q1 2020, filed 11 May 2020.